Pneumo 23

BIOLOGICAL3 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Sanofi Pasteur, a Sanofi Company, Centre Hospitalier Universitaire de Saint Etienne

Conditions

Bowel Diseases, InflammatoryInfections, PneumococcalPneumococcal InfectionsStreptococcus Pneumoniae

Phase 2

Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

TerminatedNCT02255227

Centre Hospitalier Universitaire de Saint EtienneBowel Diseases, Inflammatory, Infections, Pneumococcal

Start: 2015-04-13End: 2022-07-06Updated: 2023-06-15

Phase 3

Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

CompletedNCT00594347

Sanofi Pasteur, a Sanofi CompanyStreptococcus Pneumoniae

Start: 2007-11-30End: 2009-04-30Updated: 2015-06-18

Phase 4

Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.

TerminatedNCT00368186

Wyeth is now a wholly owned subsidiary of PfizerPneumococcal Infections

Start: 2001-05-31End: 2002-11-30Target: 51Updated: 2006-08-24